Osteopontin: Correlation with interstitial fibrosis in human diabetic kidney and PI3-kinase-mediated enhancement of expression by glucose in human proximal tubular epithelial cells

Histopathology

Volumn 44, Issue 2, 2004, Pages 136-146

  Junaid, A ^a,b   Amara, F M ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

Diabetes; Flow cytometry; Phosphatidylinositol 3 kinase; Subtractive hybridization

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; GLUCOSE; MESSENGER RNA; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOPROTEIN;

ADULT; AGED; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFERENTIAL DISPLAY; DISEASE ASSOCIATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INACTIVATION; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENCE; JUXTAGLOMERULAR APPARATUS; KIDNEY CORTEX; KIDNEY EPITHELIUM; KIDNEY FIBROSIS; KIDNEY PROXIMAL TUBULE; KIDNEY SCAR; MALE; NORTHERN BLOTTING; OSMOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; RENAL DIABETES; SUBTRACTIVE HYBRIDIZATION; UPREGULATION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AGED; AMINO ACID SEQUENCE; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELLS, CULTURED; DIABETIC NEPHROPATHIES; ENZYME INHIBITORS; EPITHELIAL CELLS; FIBROSIS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GLUCOSE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KIDNEY TUBULES, PROXIMAL; MALE; MOLECULAR SEQUENCE DATA; NEPHRITIS, INTERSTITIAL; OSTEOPONTIN; RNA, MESSENGER; SEQUENCE HOMOLOGY, AMINO ACID; SIALOGLYCOPROTEINS;

EID: 1542270075     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2004.01771.x     Document Type: Article

References (41)

1. US Renal Data System. Researchers guide to the USRDS database. Minneapolis, MN: USRDS, The National Institutes of Health, National Institute of Diabetes and Digestive Kidney Diseases, 1999.
2. Ziyadeh FN, Goldfarb S. The renal tubulointerstitium in diabetes mellitus. Kidney Int. 1991; 39; 464-475.
3. Yu XQ, Wu LL, Huang XR et al. Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II. Kidney Int. 2000; 58; 1469-1480.
4. Franzen A, Heinegard D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem. J. 1985; 232; 715-724.
5. Butler WT. The nature and significance of osteopontin. Connect. Tissue Res. 1989; 23; 123-136.
6. Brown LF, Berse B, Van de Water L et al. Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol. Biol. Cell 1992; 3; 1169-1180.
7. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993; 7; 1475-1482.
8. Singh K, Sirokman G, Communal C et al. Myocardial osteopontin expression coincides with the development of heart failure. Hypertension 1999; 33; 663-670.
9. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL. Altered wound healing in mice lacking a functional osteopontin gene (sppl). J. Clin. Invest. 1998; 101; 1468-1478.
10. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ. Res. 1994; 74; 214-224.
11. Crawford HC, Matrisian LM, Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res. 1998; 58; 5206-5215.
12. Chabas D, Baranzini SE, Mitchell D et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001; 294; 1731-1735.
13. Trueblood NA, Xie Z, Communal C et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ. Res. 2001; 88; 1080-1087.
14. Hudkins KL, Giachelli CM, Cui Y, Couser WG, Johnson RJ, Alpers CE. Osteopontin expression in fetal and mature human kidney. J. Am. Soc. Nephrol. 1999; 10; 444-457.
15. Noiri E, Dickman K, Miller F et al. Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene. Kidney Int. 1999; 56; 74-82.
16. Ophascharoensuk V, Giachelli CM, Gordon K et al. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int. 1999; 56; 571-580.
17. Hwang SM, Wilson PD, Laskin JD, Denhardt DT. Age and development-related changes in osteopontin and nitric oxide synthase mRNA levels in human kidney proximal tubule epithelial cells: contrasting responses to hypoxia and reoxygenation. J. Cell Physiol. 1994; 160; 61-68.
18. Diamond JR, Kees-Folts D, Ricardo SD, Pruznak A, Eufemio M. Early and persistent up-regulated expression of renal cortical osteopontin in experimental hydronephrosis. Am. J. Pathol. 1995; 146; 1455-1466.
19. Giachelli CM, Pichler R, Lombardi D et al. Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. Kidney Int. 1994; 45; 515-524.
20. Fischer JW, Tschope C, Reinecke A, Giachelli CM, Unger T. Upregulation of osteopontin expression in renal cortex of streptozotocin-induced diabetic rats is mediated by bradykinin. Diabetes 1998; 47; 1512-1518.
21. Kelly DJ, Wilkinson-Berka JL, Ricardo SD, Cox AJ, Gilbert RE. Progression of tubulointerstitial injury by osteopontin-induced macrophage recruitment in advanced diabetic nephropathy of transgenic (mRen-2)27 rats. Nephrol. Dial. Transplant. 2002; 17; 985-991.
22. Narita I, Nakayama H, Goto S et al. Identification of genes specifically expressed in chronic and progressive glomerulosclerosis. Kidney Int. Suppl. 1997; 63; S215-217.
23. Feliers D, Duraisamy S, Faulkner JL et al. Activation of renal signaling pathways in db/db mice with type 2 diabetes. Kidney Int. 2001; 60; 495-504.
24. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987; 162; 156-159.
25. Nath KA, Salahudeen AK. Induction of renal growth and injury in the intact rat kidney by dietary deficiency of antioxidants. J. Clin. Invest. 1990; 86; 1179-1192.
26. Lee AS. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem. Sci. 2001; 26; 504-510.
27. Persy VP, Verstrepen WA, Ysebaert DK, De Greef KE, De Broe ME. Differences in osteopontin up-regulation between proximal and distal tubules after renal ischemia/reperfusion. Kidney Int. 1999; 56; 601-611.
28. Fine LG, Orphanides C, Norman JT. Progressive renal disease: the chronic hypoxia hypothesis. Kidney Int. Suppl. 1998; 65; S74-78.
29. Sahai A, Mei C, Schrier RW, Tannen RL. Mechanisms of chronic hypoxia-induced renal cell growth. Kidney Int. 1999; 56; 1277-1281.
30. Giachelli CM, Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol. 2000; 19; 615-622.
31. Thomsen AC. The significance of renal biopsy for the diagnosis of pyelonephritis in diabetic patients. In Wolstenholme GEW, Cameron MP eds. Ciba Foundation symposium on renal biopsy. Boston: Little, Brown, 1961; 281.
32. Thomas SE, Lombardi D, Giachelli C, Bohle A, Johnson RJ. Osteopontin expression, tubulointerstitial disease, and essential hypertension. Am. J. Hypertens. 1998; 11; 954-961.
33. Sodhi CP, Phadke SA, Batlle D, Sahai A. Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: role of osteopontin. Am. J. Physiol. Renal Physiol. 2001; 280; F667-674.
34. Hudkins KL, Giachelli CM, Eitner F, Couser WG, Johnson RJ, Alpers CE. Osteopontin expression in human crescentic glomerulonephritis. Kidney Int. 2000; 57; 105-116.
35. Gabbal FB, Blantz RC. Role of nitric oxide in renal hemodynamics. Semin. Nephrol. 1999; 19; 242-250.
36. Thomson SC, Bachmann S, Bostanjoglo M et al. Temporal adjustment of the juxtaglomerular apparatus during sustained inhibition of proximal reabsorption. J. Clin. Invest. 1999; 104; 1149-1158.
37. Hwang SM, Lopez CA, Heck DE et al. Osteopontin inhibits Induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. J. Biol. Chem. 1994; 269; 711-715.
38. Pichler R, Giachelli CM, Lombardi D et al. Tubulointerstitial disease in glomerulonephritis. Potential role of osteopontin (uropontin). Am. J. Pathol. 1994; 144; 915-926.
39. Takemoto M, Yokote K, Yamazaki M et al. Enhanced expression of osteopontin by high glucose in cultured rat aortic smooth muscle cells. Biochem. Biophys. Res. Commun. 1999; 258; 722-726.
40. Sodhi CP, Phadke SA, Batlle D, Sahai A. Hypoxia stimulates osteopontin expression and proliferation of cultured vascular smooth muscle cells: potentiation by high glucose. Diabetes 2001; 50; 1482-1490.
41. Zhang Z, Yang XY, Soltoff SP, Cohen DM. PI3K signaling in the murine kidney inner medullary cell response to urea. Am. J. Physiol. Renal Physiol. 2000; 278; F155-164.